EP3463304A4 - Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations - Google Patents

Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations Download PDF

Info

Publication number
EP3463304A4
EP3463304A4 EP17802329.7A EP17802329A EP3463304A4 EP 3463304 A4 EP3463304 A4 EP 3463304A4 EP 17802329 A EP17802329 A EP 17802329A EP 3463304 A4 EP3463304 A4 EP 3463304A4
Authority
EP
European Patent Office
Prior art keywords
cannabidiol
compositions
hyaluronic acid
treating inflammatory
joint diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17802329.7A
Other languages
German (de)
English (en)
Other versions
EP3463304A1 (fr
Inventor
Tamir GEDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bol Pharma Ltd
Original Assignee
Bol Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bol Pharma Ltd filed Critical Bol Pharma Ltd
Publication of EP3463304A1 publication Critical patent/EP3463304A1/fr
Publication of EP3463304A4 publication Critical patent/EP3463304A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP17802329.7A 2016-05-24 2017-05-24 Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations Withdrawn EP3463304A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662340576P 2016-05-24 2016-05-24
PCT/IL2017/050580 WO2017203529A1 (fr) 2016-05-24 2017-05-24 Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations

Publications (2)

Publication Number Publication Date
EP3463304A1 EP3463304A1 (fr) 2019-04-10
EP3463304A4 true EP3463304A4 (fr) 2020-01-08

Family

ID=60411168

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17802329.7A Withdrawn EP3463304A4 (fr) 2016-05-24 2017-05-24 Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations

Country Status (4)

Country Link
EP (1) EP3463304A4 (fr)
CA (1) CA3025208A1 (fr)
IL (1) IL263174A (fr)
WO (1) WO2017203529A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
EP3817750A4 (fr) * 2018-07-02 2022-05-04 Companion Sciences, LLC Compositions d'associations de cannabidiol
WO2020021545A1 (fr) * 2018-07-25 2020-01-30 Bol Pharma Ltd. Cannabidiol et glucosamine pour le traitement de maladies articulaires inflammatoires
WO2020024056A1 (fr) * 2018-08-01 2020-02-06 Lazar Eve Compositions comprenant des cannabinoïdes et matériau absorbable et utilisations associées
PE20211198A1 (es) * 2018-10-10 2021-07-01 Tilray Inc Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia
KR20210114409A (ko) * 2018-12-11 2021-09-23 디스럽션 랩스 인코퍼레이티드 치료제 전달용 조성물과 이의 이용 및 제조 방법
US20220054532A1 (en) * 2019-03-05 2022-02-24 Colleen Smith Veterinary compositions and methods of use therefor
US20200352849A1 (en) * 2019-05-07 2020-11-12 Adam M. Rotunda Topical Skin Formulations and Wound Care Products with Integrated CBD Delivery Mechanisms for Skin Rejuvenation, Wound Care and Healing, Pain and Itch Relief, and Scar Prevention and Treatment
IT201900008409A1 (it) * 2019-06-07 2020-12-07 Vivatis Pharma Gmbh Individuazione e selezione di un materiale di partenza vegetale di condroitina solfato e acido ialuronico vegetali, e trasformazione di tale materiale di partenza vegetale per l’ottenimento di ingredienti per utilizzo in alimenti, integratori, dispositivi medici o farmaci
CA3156487A1 (fr) * 2019-10-03 2021-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoides liposomiques et utilisations associees
WO2021091905A1 (fr) * 2019-11-08 2021-05-14 Vella Bioscience, Inc. Formulations liposomales pour l'administration de cannabinoïdes et leurs procédés de fabrication
AU2020399792A1 (en) * 2019-12-13 2022-07-21 Folium Labs Inc. Complexes comprising a carbohydrate polymer and an active ingredient and processes for their preparation
GB201918846D0 (en) * 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
EP3861996A1 (fr) 2020-02-04 2021-08-11 I+Med S. Coop. Système de libération contrôlée de formulations de phytocannabinoïdes solubles dans un milieu aqueux, procédés et utilisations associés
CN112138138B (zh) * 2020-11-19 2023-05-23 乐康珍泰（天津）生物技术有限公司 一种用于治疗痛风的药物组合物及其制备方法
CA3217137A1 (fr) 2021-04-29 2022-11-03 Christopher Adair Formulations dans lesquelles le cannabidiol est le constituant dominant, leurs procedes de fabrication et leurs utilisations
CA3217973A1 (fr) * 2021-05-03 2022-11-10 Donald L. Simmons Compositions topiques de polyphenol de liposome pour le traitement et la prevention de divers troubles de la peau et leurs procedes de preparation
IT202200002000A1 (it) * 2022-02-04 2023-08-04 Mak Pharma S R L Composizione orale liposomiale di almeno un principio attivo scarsamente assorbibile a livello intestinale

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120478A1 (fr) * 2004-06-08 2005-12-22 Gw Pharma Limited Compositions pharmaceutiques destinees au traitement de l'arthrite et/ou de ses symptomes
WO2009018389A1 (fr) * 2007-07-30 2009-02-05 Alltranz Inc. Promédicaments de cannabidiol, compositions comprenant les promédicaments de cannabidiol et leurs procédés d'utilisation
EP2446884A1 (fr) * 2010-10-29 2012-05-02 China Medical University Composition pharmaceutique comprenant de l'acide hyaluronique et un inhibiteur de l'HMG-CoA réductase pour inhiber l'inflammation
WO2014008469A2 (fr) * 2012-07-05 2014-01-09 Taiwan Liposome Company, Ltd. Méthodes de traitement de l'arthrite

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
WO2009073843A1 (fr) * 2007-12-06 2009-06-11 Cytotech Labs, Llc Compositions inhalables présentant une meilleure biodisponibilité
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
US20150004219A1 (en) * 2012-02-02 2015-01-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Stable liposomes for drug delivery
JP2016537412A (ja) * 2013-10-31 2016-12-01 フル スペクトラム ラボラトリーズ，エルティーディー． テルペン及びカンナビノイドの製剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120478A1 (fr) * 2004-06-08 2005-12-22 Gw Pharma Limited Compositions pharmaceutiques destinees au traitement de l'arthrite et/ou de ses symptomes
WO2009018389A1 (fr) * 2007-07-30 2009-02-05 Alltranz Inc. Promédicaments de cannabidiol, compositions comprenant les promédicaments de cannabidiol et leurs procédés d'utilisation
EP2446884A1 (fr) * 2010-10-29 2012-05-02 China Medical University Composition pharmaceutique comprenant de l'acide hyaluronique et un inhibiteur de l'HMG-CoA réductase pour inhiber l'inflammation
WO2014008469A2 (fr) * 2012-07-05 2014-01-09 Taiwan Liposome Company, Ltd. Méthodes de traitement de l'arthrite

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017203529A1 *

Also Published As

Publication number Publication date
WO2017203529A1 (fr) 2017-11-30
EP3463304A1 (fr) 2019-04-10
IL263174A (en) 2018-12-31
CA3025208A1 (fr) 2017-11-30

Similar Documents

Publication Publication Date Title
EP3463304A4 (fr) Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations
EP3347368A4 (fr) Composés et formulations pour traiter les maladies ophthalmiques
EP3389672A4 (fr) Compositions et procédés de traitement de maladies hépatiques
EP3261440A4 (fr) Méthodes et compositions de traitement de maladies oculaires génétiques
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3177732A4 (fr) Compositions et procédés pour le traitement de maladies et états pathologiques ophthalmiques
EP3096617A4 (fr) Compositions et méthodes de traitement de maladies oculaires
EP3319976A4 (fr) Compositions et procédés pour traiter des maladies pulmonaires et des lésions pulmonaires
EP3390666A4 (fr) Compositions et méthodes de traitement de maladies rénales
EP3592345A4 (fr) Compositions et méthodes pour le traitement de maladies inflammatoires
EP3826666A4 (fr) Compositions et méthodes de traitement de maladies associées à la nrp2
EP3139928A4 (fr) Compositions d'anordrine et méthodes de traitement de maladies
EP3716990A4 (fr) Compositions et procédés de traitement de maladies neurologiques
EP3148575A4 (fr) Méthodes et compositions de traitement d'allergie et les maladies inflammatoires
EP3110446A4 (fr) Procédés et compositions pour le traitement de maladies associées à siglec-8
EP3818081A4 (fr) Compositions et méthodes pour le traitement de maladies ou de troubles liés aux inflammasomes
EP3570670A4 (fr) Compositions et procédés de traitement de maladies et de troubles du stockage lysosomial
EP3481958A4 (fr) Procédés et compositions de traitement de troubles et de maladies impliquant rdh12
EP3275450A4 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies inflammatoires, contenantlactococcus chungangensis
EP3164132A4 (fr) Méthodes et compositions pour le traitement de maladies et d'affections
EP3393460A4 (fr) Compositions et procédés de traitement de la miv et de maladies associées
EP3265103A4 (fr) Compositions et méthodes de traitement de maladies oculaires
EP3119387A4 (fr) Compositions pour le traitement de maladies et de troubles dermatologiques
EP3430017A4 (fr) Compositions et méthodes pour traiter les parasitoses
EP3364965A4 (fr) Méthodes et compositions pour le traitement de maladies neurodégénératives

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191211

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/127 20060101AFI20191205BHEP

Ipc: A61K 47/24 20060101ALI20191205BHEP

Ipc: A61P 19/02 20060101ALI20191205BHEP

Ipc: A61K 47/36 20060101ALI20191205BHEP

Ipc: A61K 31/352 20060101ALI20191205BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20211201